首页 | 本学科首页   官方微博 | 高级检索  
     

Ph染色体阳性成人急性淋巴细胞白血病患者预后相关因素分析
引用本文:刘世和,秘营昌,刘旭平,薛艳萍,王慧君,卞寿庚,王建祥. Ph染色体阳性成人急性淋巴细胞白血病患者预后相关因素分析[J]. 中华血液学杂志, 2004, 25(7): 417-420
作者姓名:刘世和  秘营昌  刘旭平  薛艳萍  王慧君  卞寿庚  王建祥
作者单位:300020,天津,中国医学科学院、中国协和医科大学血液学研究所、血液病医院
摘    要:目的 分析影响Ph 成人急性淋巴细胞白血病 (aALL)患者生存的各种相关因素。方法 综合分析 31例Ph aALL相关临床参数 ,观察生存期 ,并进行统计学分析。结果 Ph aALL占所有统计aALL的 15 .3%。临床上表现为年龄偏高 ,白细胞计数、幼稚细胞数高 ,血小板计数较低。免疫分型诊断以Common型为主 (82 .6 % ,2 3例中有 19例 ) ,39.1% (2 3例中有 7例 )协同表达髓系抗原 ,CD34 患者占 5 6 .5 % (2 3例中有 13例 )。缓解率 6 5 .4 % ,中位缓解期 4个月 ,中位生存期 8个月。Ph伴附加染色体异常占Ph阳性总数的 4 2 % ,常见的附加染色体异常包括 - 7, Ph ,del(9) (p11 12 ) ,add/t(16 ) (p13)等。Ph伴附加染色体异常组血小板计数显著低于单纯Ph 组 (P =0 .0 12 )和变异Ph易位组 (P =0 .0 0 1)。免疫分型研究显示CD34 患者组缓解期及生存期显著短于阴性组 (缓解期分别为 0和 9个月 ,P =0 .0 2 4 ;生存期分别为 6个月和 12个月 ,P =0 .0 34) ,但髓系抗原协同表达与否不影响生存期。结论 Ph aALL是一组预后不良的患者群 ,Ph合并附加染色体异常与否和临床异质性无显著相关 ,CD34表达在Ph aALL中是一个不良的预后因素。

关 键 词:白血病  淋巴细胞  急性  成人  费城染色体  预后  抗原  CD34
修稿时间:2003-07-15

Analysis of factors associated with prognosis in patients with Ph chromosome positive adult acute lymphoblastic leukemia
Shi-he Liu,Ying-chang Mi,Xu-ping Liu,Yan-ping Xue,Hui-jun Wang,Shou-geng Bian,Jian-xiang Wang. Analysis of factors associated with prognosis in patients with Ph chromosome positive adult acute lymphoblastic leukemia[J]. Chinese Journal of Hematology, 2004, 25(7): 417-420
Authors:Shi-he Liu  Ying-chang Mi  Xu-ping Liu  Yan-ping Xue  Hui-jun Wang  Shou-geng Bian  Jian-xiang Wang
Affiliation:Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
Abstract:Objective To investigate factors associated with survival of patients with Ph chromosome positive adult acute lymphoblastic leukemia (aALL) in a period of 11 years. Methods All the clinical parameters of 31 Ph positive patients were statistically analyzed by SPSS software. Result Ph patients account for 15.3%(31/203) of all the aALL patients. Clinically, these patients manifested older in age, higher white blood cell counts with high blast fractions and lower platelet counts (PC). Phenotypically 82.6% of them were common ALL, 39.1% coexpressed myeloid antigens, and 56.5% expressed CD34 antigen. 65.4% of them (17/26) achieved complete remission (CR) and the median remission and survival durations were 4 months and 8 months, respectively. Patients with Ph and additional chromosomal aberrations accounted for 42% of all the Ph patients, including monosomy 7, Ph, del(9)(p11 12) and add/t(16)(p13), and they had lower PC as compared with those with sole Ph (P=0.012) and variant Ph translocation (P=0.01). CD34 positive patients had a shorter remission and survival duration than CD34 negative ones (0 vs 9 months for median remission time, P= 0.024 ; and 6 vs 12 months for median survival time, P=0.034). There was no evidence to support the correlation between myeloid antigen expression and survival time in these patients. Conclusion Ph aALL is associated with adverse prognosis and CD34 expression is a poorer prognostic factor in Ph aALL patients. There is no significant clinical difference between Ph aALL with or without additional chromosomal aberrations.
Keywords:Leukemia  lymphocytic  acute  Adult  Philadelphia chromosome  Prognosis  Antigens   CD34
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号